Ipilimumab

CTLA-4-directed Blocking Antibody — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Ipilimumab is a drug in the CTLA-4-directed Blocking Antibody class catalogued in DrugCentral. It was first approved by the FDA in 2011. Its mechanism of action is classified as CTLA-4-directed Antibody Interactions. DrugCentral lists 1 molecular target, including CTLA4. Recorded indications include High grade squamous intraepithelial neoplasia of esophagus, Metastatic malignant melanoma, Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation and Microsatellite instability-high colorectal cancer.

• Drug class: CTLA-4-directed Blocking Antibody.
• Mechanism of action: CTLA-4-directed Antibody Interactions.
• Molecular targets: CTLA4 (1 listed in DrugCentral).
• Indications: High grade squamous intraepithelial neoplasia of esophagus, Metastatic malignant melanoma, Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation, Microsatellite instability-high colorectal cancer and Renal cell carcinoma and others.
• ATC code: L01FX04 (Other monoclonal antibodies and antibody drug conjugates).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

• High grade squamous intraepithelial neoplasia of esophagus
• Metastatic malignant melanoma
• Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation
• Microsatellite instability-high colorectal cancer
• Renal cell carcinoma
• Unresectable advanced or recurrent esophageal cancer
• Unresectable advanced or recurrent malignant pleural mesothelioma

Mechanism & targets

• Mechanism of action (MoA): CTLA-4-directed Antibody Interactions
• Established pharmacologic class: CTLA-4-directed Blocking Antibody

Molecular targets (1)

Target	Gene	Action	Activity
Cytotoxic T-lymphocyte protein 4	CTLA4	unknown	Kd 8.07

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2015-07-03	PMDA	—	BRISTOL-MYERS SQUIBB K.K	Yes
2011-07-13	EMA	—	—
2011-03-25	FDA	—	BRISTOL MYERS SQUIBB	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01FX04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: ALK, CD274, EGFR · Testing Required
• EMA label: HLA-A · No Clinical PGx
• FDA label: ALK, CD274, EGFR · Testing Required
• FDA label: HLA-A · No Clinical PGx
• HCSC label: ALK, CD274, EGFR · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Malignant neoplasm progression	6179.1
Immune-mediated enterocolitis	4222.6
Hypophysitis	4057.6
Colitis	3986.5
Death	2012.8
Adrenal insufficiency	1746.7
Immune-mediated hepatitis	1726.8
Hypopituitarism	1459.3
Pneumonitis	1458.5
Immune-mediated hepatic disorder	1429.2
Immune-mediated lung disease	1293.5
Hypothyroidism	1153.3

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ipilimumab used for?

DrugCentral lists the following indications for Ipilimumab: High grade squamous intraepithelial neoplasia of esophagus, Metastatic malignant melanoma, Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation, Microsatellite instability-high colorectal cancer, Renal cell carcinoma, Unresectable advanced or recurrent esophageal cancer and Unresectable advanced or recurrent malignant pleural mesothelioma.

How does Ipilimumab work?

Ipilimumab is classified as CTLA-4-directed Antibody Interactions; its molecular targets in DrugCentral include CTLA4.

When was Ipilimumab first approved?

Ipilimumab was first approved by the FDA in 2011.

What drug class does Ipilimumab belong to?

Ipilimumab is in the CTLA-4-directed Blocking Antibody class.

Sources

• DrugCentral drug card 4958 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1789844 — compound record and bioactivity
• DrugBank DB06186 — drug record
• FDA UNII 6T8C155666 — substance identity
• DailyMed: FDA labels for Ipilimumab — current prescribing information (label search)
• UniProt P16410 (CTLA4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.